November 10, 2022
A West Virginia federal judge has granted drugmaker Viatris' bid to invalidate one of rival AstraZeneca's patents on brand name asthma treatment Symbicort, determining that the challenged claims are invalid for lack of enablement and lack of written description.
March 03, 2021
AstraZeneca scored a win in a suit accusing Mylan Pharmaceuticals of infringing patents for its asthma treatment Symbicort when a West Virginia federal judge on Tuesday shot down arguments that the patents were invalid.